Mackenzie Financial
SPRO icon

Mackenzie Financial’s Spero Therapeutics SPRO Stock Holding History

Mackenzie Financial’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-209,031
Closed -$151K – 1792
2025
Q1 		$151K Buy
209,031
+21,472
+11% +$18.1K ﹤0.01% 1554
2024
Q4 		$193K Buy
187,559
+155,656
+488% +$185K ﹤0.01% 1569
2024
Q3 		$42.8K Sell
31,903
-826
-3% -$1.11K ﹤0.01% 1545
2024
Q2 		$42.5K Buy
32,729
+4,287
+15% +$6.47K ﹤0.01% 1500
2024
Q1 		$48.9K Buy
28,442
+6,980
+33% +$10.9K ﹤0.01% 1484
2023
Q4 		$31.5K Buy
21,462
+4,264
+25% +$5.08K ﹤0.01% 1471
2023
Q3 		$20.1K Hold
17,198
– – ﹤0.01% 1452
2023
Q2 		$25.3K Buy
+17,198
New +$29.4K ﹤0.01% 1491

Other funds holding SPRO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $432M AUM 20.27% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Mackenzie Financial's SPRO Position: Q2 2025 in Review

Mackenzie Financial sold out of Spero Therapeutics (SPRO) in Q2 2025, closing a stake of 209,031 shares — an estimated $151K sold.

Mackenzie Financial first reported a position in SPRO in Q2 2023 and held it in 8 quarters. The position peaked at $193K in Q4 2024. 44 funds tracked by Wall St. Rank hold SPRO as of Q2 2025.

  • Mackenzie Financial reported no remaining Spero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mackenzie Financial sold 209,031 Spero Therapeutics shares in Q2 2025, an estimated $151K.
  • Mackenzie Financial first reported a position in Spero Therapeutics in Q2 2023 and held it in 8 quarters.
  • Mackenzie Financial's Spero Therapeutics position peaked at $193K in Q4 2024.
  • 44 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2025.

Based on Mackenzie Financial's 13F filing for Q2 2025, filed 13 Aug 2025.